DE60224004T2 - Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten - Google Patents

Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten Download PDF

Info

Publication number
DE60224004T2
DE60224004T2 DE60224004T DE60224004T DE60224004T2 DE 60224004 T2 DE60224004 T2 DE 60224004T2 DE 60224004 T DE60224004 T DE 60224004T DE 60224004 T DE60224004 T DE 60224004T DE 60224004 T2 DE60224004 T2 DE 60224004T2
Authority
DE
Germany
Prior art keywords
inhibitor
use according
antibody
tnf
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224004T
Other languages
German (de)
English (en)
Other versions
DE60224004D1 (de
Inventor
Charles Boulder DINARELLO
Benjamin University City POMERANTZ
Leonid Denver REZNIKOV
Alden Littleton HARKEN
Yolande Chvatchko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Serono Laboratories UK Ltd
Original Assignee
Laboratoires Serono SA
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Serono Laboratories UK Ltd filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of DE60224004D1 publication Critical patent/DE60224004D1/de
Publication of DE60224004T2 publication Critical patent/DE60224004T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60224004T 2001-01-29 2002-01-28 Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten Expired - Lifetime DE60224004T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29
EP01101959 2001-01-29
PCT/EP2002/000844 WO2002060479A1 (en) 2001-01-29 2002-01-28 Use of il-18 inhibitors for the treatment and/or prevention of heart disease

Publications (2)

Publication Number Publication Date
DE60224004D1 DE60224004D1 (de) 2008-01-24
DE60224004T2 true DE60224004T2 (de) 2009-07-23

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224004T Expired - Lifetime DE60224004T2 (de) 2001-01-29 2002-01-28 Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten

Country Status (31)

Country Link
US (1) US20040234523A1 (cg-RX-API-DMAC10.html)
EP (1) EP1355668B1 (cg-RX-API-DMAC10.html)
JP (2) JP4860897B2 (cg-RX-API-DMAC10.html)
KR (1) KR100857376B1 (cg-RX-API-DMAC10.html)
CN (1) CN1326562C (cg-RX-API-DMAC10.html)
AR (1) AR032422A1 (cg-RX-API-DMAC10.html)
AT (1) ATE380558T1 (cg-RX-API-DMAC10.html)
BG (1) BG66483B1 (cg-RX-API-DMAC10.html)
BR (1) BR0206819A (cg-RX-API-DMAC10.html)
CA (1) CA2435466C (cg-RX-API-DMAC10.html)
CY (1) CY1107203T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ305653B6 (cg-RX-API-DMAC10.html)
DE (1) DE60224004T2 (cg-RX-API-DMAC10.html)
DK (1) DK1355668T3 (cg-RX-API-DMAC10.html)
EA (2) EA006767B1 (cg-RX-API-DMAC10.html)
EE (1) EE05534B1 (cg-RX-API-DMAC10.html)
ES (1) ES2295332T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20030609A2 (cg-RX-API-DMAC10.html)
HU (1) HU229164B1 (cg-RX-API-DMAC10.html)
IL (2) IL157024A0 (cg-RX-API-DMAC10.html)
ME (1) ME00549B (cg-RX-API-DMAC10.html)
MX (1) MXPA03006776A (cg-RX-API-DMAC10.html)
NO (1) NO331083B1 (cg-RX-API-DMAC10.html)
PL (1) PL213568B1 (cg-RX-API-DMAC10.html)
PT (1) PT1355668E (cg-RX-API-DMAC10.html)
RS (1) RS51125B (cg-RX-API-DMAC10.html)
SI (1) SI1355668T1 (cg-RX-API-DMAC10.html)
SK (1) SK287620B6 (cg-RX-API-DMAC10.html)
UA (1) UA80676C2 (cg-RX-API-DMAC10.html)
WO (1) WO2002060479A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200305439B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
AU2004238524B2 (en) 2003-05-13 2011-06-23 Merck Serono Sa Active variants of the IL-18 binding protein and medical uses thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
TW200927060A (en) 2007-11-05 2009-07-01 Kci Licensing Inc Identification of tissue for debridement
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
JP4094066B2 (ja) * 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165490B1 (en) * 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CA2369619A1 (en) * 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
CA2407895C (en) * 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CN1326562C (zh) 2007-07-18
JP2009102354A (ja) 2009-05-14
YU57803A (sh) 2006-05-25
PT1355668E (pt) 2008-01-04
NO331083B1 (no) 2011-10-03
EE05534B1 (et) 2012-04-16
AR032422A1 (es) 2003-11-05
DE60224004D1 (de) 2008-01-24
EA200501549A1 (ru) 2006-04-28
JP4860897B2 (ja) 2012-01-25
ZA200305439B (en) 2004-07-15
EE200300328A (et) 2003-10-15
HUP0303306A3 (en) 2005-12-28
EA006767B1 (ru) 2006-04-28
EA010180B1 (ru) 2008-06-30
CZ305653B6 (cs) 2016-01-27
HK1062810A1 (en) 2004-11-26
WO2002060479A1 (en) 2002-08-08
IL157024A (en) 2014-02-27
PL366802A1 (en) 2005-02-07
ME00549B (me) 2011-10-10
BG108128A (bg) 2004-11-30
BG66483B1 (bg) 2015-03-31
JP2004522748A (ja) 2004-07-29
CN1499982A (zh) 2004-05-26
CA2435466A1 (en) 2002-08-08
BR0206819A (pt) 2004-02-03
NO20033228L (no) 2003-09-26
HRP20030609A2 (en) 2005-06-30
HU229164B1 (en) 2013-09-30
EA200300844A1 (ru) 2003-12-25
CY1107203T1 (el) 2012-11-21
EP1355668B1 (en) 2007-12-12
HUP0303306A2 (hu) 2004-01-28
PL213568B1 (pl) 2013-03-29
MXPA03006776A (es) 2003-10-24
ES2295332T3 (es) 2008-04-16
NO20033228D0 (no) 2003-07-16
EP1355668A1 (en) 2003-10-29
RS51125B (sr) 2010-10-31
UA80676C2 (en) 2007-10-25
ATE380558T1 (de) 2007-12-15
SK10892003A3 (sk) 2004-02-03
CA2435466C (en) 2012-04-03
DK1355668T3 (da) 2008-05-05
KR100857376B1 (ko) 2008-09-05
SI1355668T1 (sl) 2008-06-30
IL157024A0 (en) 2004-02-08
CZ20032335A3 (en) 2004-07-14
US20040234523A1 (en) 2004-11-25
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05

Similar Documents

Publication Publication Date Title
DE60034579T2 (de) Baff rezeptor (bcma), ein immunoregulatorisches mittel
JP2009102354A (ja) 心疾患の治療および／または予防のためのｉｌ−１８阻害剤の使用
EP1997512B1 (en) Methods for treating TWEAK-related conditions
DE60033431T2 (de) Chimärische natriuretische peptide
DE69934308T2 (de) Il-6-antagonist peptide
NO336226B1 (no) Anvendelse av IL-18-inhibitorer i fremstilling av et medikament for behandlingen og/eller forebyggingen av perifere vaskulære sykdommer i ekstremitetene
DE69736244T2 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
US7304040B2 (en) Suppression of post-transplant arteriosclerosis
DE69535091T2 (de) Humane prostacyclinsynthase
AU2002249144B2 (en) Use of IL-18 inhibitors for the treatment and/or prevention of heart disease
DE19725186C2 (de) Herz- und Skelettmuskel-spezifische Nukleinsäure, ihre Herstellung und Verwendung
HK1062810B (en) Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heart disease
DE19813774A1 (de) Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
AU2002249144A1 (en) Use of IL-18 inhibitors for the treatment and/or prevention of heart disease
RS57803B1 (sr) Biokompatibilni mikroemulzioni sistemi sa kontrolisanim oslobađanjem ibuprofena, njihovo dobijanje i primena
HK1066723B (en) Use of il-18 inhibitors for the treatment or prevention of sepsis
HK1066723A1 (en) Use of il-18 inhibitors for the treatment or prevention of sepsis
HK1127545B (en) Methods for treating tweak-related conditions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition